Literature DB >> 12777705

Estrogen as neuroprotectant of nigrostriatal dopaminergic system: laboratory and clinical studies.

Dean Dluzen1, Martin Horstink.   

Abstract

In this review, we relate both laboratory and clinical evidence associated with the capacity for estrogen to function as a modulator of nigrostriatal dopaminergic pathology. To accomplish this goal, we have divided this review into three parts. In Part 1, we provide a brief historical perspective of studies that have laid the groundwork for demonstrating the existence of hormonal- nigrostriatal interactions. In Part 2, we focus specifically on laboratory data that show the ability and conditions by which estrogen may function as a neuroprotectant of the nigrostriatal dopaminergic system. Finally, in Part 3, we review the clinical literature related to this issue as a means for consideration of estrogen as a modulator, neuroprotectant, and therapy for Parkinson disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12777705     DOI: 10.1385/endo:21:1:67

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  97 in total

1.  Influence of gonadal hormones on sexual differences in sensitivity to methamphetamine-induced neurotoxicity.

Authors:  Y L Yu; G C Wagner
Journal:  J Neural Transm Park Dis Dement Sect       Date:  1994

2.  Estrogen as a neuroprotectant against MPTP-induced neurotoxicity in C57/B1 mice.

Authors:  D E Dluzen; J L McDermott; B Liu
Journal:  Neurotoxicol Teratol       Date:  1996 Sep-Oct       Impact factor: 3.763

3.  Estrogen use among nursing home residents with a diagnosis of Parkinson's disease.

Authors:  H H Fernandez; K L Lapane
Journal:  Mov Disord       Date:  2000-11       Impact factor: 10.338

Review 4.  Tardive dyskinesia in patients treated with major neuroleptics: a review of the literature.

Authors:  G E Crane
Journal:  Am J Psychiatry       Date:  1968-02       Impact factor: 18.112

5.  Effects of female sex steroids on Parkinson's disease in postmenopausal women.

Authors:  E Strijks; J A Kremer; M W Horstink
Journal:  Clin Neuropharmacol       Date:  1999 Mar-Apr       Impact factor: 1.592

6.  Hysterectomy, menopause, and estrogen use preceding Parkinson's disease: an exploratory case-control study.

Authors:  M D Benedetti; D M Maraganore; J H Bower; S K McDonnell; B J Peterson; J E Ahlskog; D J Schaid; W A Rocca
Journal:  Mov Disord       Date:  2001-09       Impact factor: 10.338

7.  Oestrogens and extrapyramidal system.

Authors:  P Bedard; P Langelier; A Villeneuve
Journal:  Lancet       Date:  1977 Dec 24-31       Impact factor: 79.321

8.  [Angiodysplasia of moya-moya type disclosed by choreic unvoluntary abnormal movements during oral contraception. Apropos of 2 cases].

Authors:  J Pelletier; C Cabanot; O Lévrier; J N Thuillier; A A Chérif
Journal:  Rev Neurol (Paris)       Date:  1997-07       Impact factor: 2.607

9.  Sex differences and estrous cycle variations in amphetamine-elicited rotational behavior.

Authors:  J B Becker; T E Robinson; K A Lorenz
Journal:  Eur J Pharmacol       Date:  1982-05-07       Impact factor: 4.432

10.  Stereotyped behavior elicited by amphetamine in the rat: influences of the testes.

Authors:  W W Beatty; A M Dodge; K L Traylor
Journal:  Pharmacol Biochem Behav       Date:  1982-04       Impact factor: 3.533

View more
  28 in total

1.  Sex-dependent antipsychotic capacity of 17β-estradiol in the latent inhibition model: a typical antipsychotic drug in both sexes, atypical antipsychotic drug in males.

Authors:  Michal Arad; Ina Weiner
Journal:  Neuropsychopharmacology       Date:  2010-07-07       Impact factor: 7.853

2.  Effects of age, gender, and gonadectomy on neurochemistry and behavior in animal models of Parkinson's disease.

Authors:  Andrea Tamás; Andrea Lubics; István Lengvári; Dóra Reglodi
Journal:  Endocrine       Date:  2006-04       Impact factor: 3.633

Review 3.  Effects of the Menstrual Cycle on Neurological Disorders.

Authors:  Hannah J Roeder; Enrique C Leira
Journal:  Curr Neurol Neurosci Rep       Date:  2021-05-10       Impact factor: 5.081

Review 4.  Neurotrophic and neuroprotective actions of estrogen: basic mechanisms and clinical implications.

Authors:  Darrell W Brann; Krishnan Dhandapani; Chandramohan Wakade; Virendra B Mahesh; Mohammad M Khan
Journal:  Steroids       Date:  2007-02-21       Impact factor: 2.668

Review 5.  Estrogen actions in the brain and the basis for differential action in men and women: a case for sex-specific medicines.

Authors:  Glenda E Gillies; Simon McArthur
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

6.  Contrasting effects of increased and decreased dopamine transmission on latent inhibition in ovariectomized rats and their modulation by 17beta-estradiol: an animal model of menopausal psychosis?

Authors:  Michal Arad; Ina Weiner
Journal:  Neuropsychopharmacology       Date:  2010-03-17       Impact factor: 7.853

7.  Estrogen, testosterone, and sequential movement in men.

Authors:  Jessica A Siegel; Laura A Young; Michelle B Neiss; Mary H Samuels; Charles E Roselli; Jeri S Janowsky
Journal:  Behav Neurosci       Date:  2008-10       Impact factor: 1.912

Review 8.  Cytochrome P450-mediated estrogen catabolism therapeutic avenues in epilepsy.

Authors:  Megha Gautam; Ganesh Thapa
Journal:  Acta Neurol Belg       Date:  2020-08-02       Impact factor: 2.396

9.  Thalamo-Basal Ganglia connectivity in postmenopausal women receiving estrogen therapy.

Authors:  Heather A Kenna; Natalie L Rasgon; Cheri Geist; Gary Small; Daniel Silverman
Journal:  Neurochem Res       Date:  2008-06-06       Impact factor: 3.996

10.  The potential for estrogens in preventing Alzheimer's disease and vascular dementia.

Authors:  James W Simpkins; Evelyn Perez; Xiaofei Wang; Shaohua Yang; Yi Wen; Meharvan Singh
Journal:  Ther Adv Neurol Disord       Date:  2009-01       Impact factor: 6.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.